Lipocine Inc. 8-K Filing
Ticker: LPCN · Form: 8-K · Filed: Nov 18, 2025 · CIK: 1535955
| Field | Detail |
|---|---|
| Company | Lipocine Inc. (LPCN) |
| Form Type | 8-K |
| Filed Date | Nov 18, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Lipocine Inc. (ticker: LPCN) to the SEC on Nov 18, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (ch registered Common Stock, par value $0.0001 per share LPCN The NASDAQ Stock Mar).
How long is this filing?
Lipocine Inc.'s 8-K filing is 2 pages with approximately 452 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 452 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2025-11-18 09:30:24
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share LPCN The NASDAQ Stock Mar
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex99-1.htm (EX-99.1) — 21KB
- form8-k_001.jpg (GRAPHIC) — 6KB
- 0001493152-25-024011.txt ( ) — 243KB
- lpcn-20251118.xsd (EX-101.SCH) — 3KB
- lpcn-20251118_lab.xml (EX-101.LAB) — 33KB
- lpcn-20251118_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIPOCINE INC. Date: November 18, 2025 By: /s/ Mahesh V. Patel Mahesh V. Patel President and Chief Executive Officer